Skip to content

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

Peter Pushko, Paul Pumpens, Elmars Grens

Intervirology · 2013 · 5,975 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Pushko, P., Pumpens, P., & Grens, E. (2013). Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology, 56(3), 141–165. https://doi.org/10.1159/000346773

In text: (Pushko et al., 2013)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

On October 16, 2009, the Food and Drug Administration licensed quadrivalent human papillomavirus vaccine (HPV4; Gardasil, Merck & Co. Inc.) for use in males aged 9 through 26 years for prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. HPV4 had been licensed previously for use in females aged 9 through 26 years for prevention of HPV 6, 11, 16, and 18-related outcomes (i.e., vaginal, vulvar, and cervical precancers and cancers and genital warts). The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of females at age 11 or 12 years and catch-up vaccination for females aged 13 through 26 years. On October 21, 2009, ACIP provided guidance that HPV4 may be given to males aged 9 through 26 years to reduce their likelihood of acquiring genital warts; ACIP does not recommend HPV4 for routine use among males. This report presents the ACIP policy statement and summarizes background data. Issues reviewed by ACIP included efficacy, immunogenicity, and safety of the HPV4 vaccine in males, epidemiology of HPV and burden of HPV-associated diseases and cancers in males, cost-effectiveness of male vaccination, and programmatic considerations.

  1. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei1983
  2. A Third-Generation Lentivirus Vector with a Conditional Packaging System1998

Metadata from OpenAlex (CC0). Citations are generated from the published record.